Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Pin-Dong Li"'
Publikováno v:
Cancer Medicine, Vol 8, Iss 13, Pp 5969-5978 (2019)
Abstract Background Inhibitors of programmed cell death‐1 (PD‐1) and its ligand (PD‐L1) have been increasingly used in head and neck cancer therapy and reported to improve the outcomes with an acceptable safety profile. This systematic review a
Externí odkaz:
https://doaj.org/article/bc05e3877b66412094804d662bec26b9
Publikováno v:
Redox Biology, Vol 16, Iss , Pp 226-236 (2018)
Thyroid cancer is the most common endocrine carcinoma with increasing incidence worldwide and anaplastic subtypes are frequently associated with cancer related death. Radioresistance of thyroid cancer often leads to therapy failure and cancer-related
Externí odkaz:
https://doaj.org/article/0b0f4a3ffd3740b69986335569a9d4e1
Autor:
Ting Liu, Xue-feng Kan, Charlie Ma, Li-li Chen, Tian-tian Cheng, Zhen-wei Zou, Yong Li, Feng-jun Cao, Wen-jie Zhang, Jing Yao, Pin-dong Li
Publikováno v:
Tumor Biology, Vol 39 (2017)
Glutathione peroxidase 2 has important role of tumor progression in lots of carcinomas, yet little is known about the prognosis of glutathione peroxidase 2 in hepatocellular carcinoma. Glutathione peroxidase 2 expression was assessed by immunohistoch
Externí odkaz:
https://doaj.org/article/240973768fbc4417a5fbe80e2110e66f
Autor:
Yin-Lian Cha, Pin-Dong Li, Lin-Jing Yuan, Mei-Yin Zhang, Yao-Jun Zhang, Hui-Lan Rao, Hui-Zhong Zhang, X F Steven Zheng, Hui-Yun Wang
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0117493 (2015)
EIF4EBP1 acts as a crucial effector in mTOR signaling pathway. Studies have suggested that EIF4EBP1 plays a critical role in carcinogenesis. However, the clinical significance and biological role of EIF4EBP1 in hepatocellular carcinoma (HCC) have not
Externí odkaz:
https://doaj.org/article/ed059033fc78493aa0b38904ff664c98
Publikováno v:
Neoplasma. 69:331-340
Numerous studies have confirmed the anticancer effects of ferroptosis on a wide range of tumors, specifically in providing new perspectives for tackling drug resistance and treating refractory tumors. Notably, mechanisms of improving tumor susceptibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59ecd1911dfd0298b4edd09f982c2dc7
https://doi.org/10.4149/neo_2021_210810n1132
https://doi.org/10.4149/neo_2021_210810n1132
Autor:
Bi-Cheng Wang, Bo-Ya Xiao, Peng-Cheng Li, Bo-Hua Kuang, Wang-Bing Chen, Pin-Dong Li, Guo-He Lin, Quentin Liu, San Lin You
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2020 (2020)
Journal of Oncology, Vol 2020 (2020)
Background. The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21546d36e356311fb305e78c056eb75f
http://europepmc.org/articles/PMC7542505
http://europepmc.org/articles/PMC7542505
Autor:
Jing Chen, Xiao Fang Dai, Zhao Liu, Li-Li Chen, Charlie Ma, Wen Guang Luo, Tian Tian Cheng, Zhen Wei Zou, Pin Dong Li, Jing Yao
Publikováno v:
Oncotarget
Glutathione is the major intracellular anti-oxidant against reactive oxygen species and serves as a detoxification essential. The anti-diabetic drug metformin has been showed to exert anti-tumor activity via modulation of redox homeostasis. In this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63c6bfdc121a9c87176a091f3766d83
https://doi.org/10.18632/oncotarget.18907
https://doi.org/10.18632/oncotarget.18907
Autor:
Wang Bing Chen, Quentin Liu, Xiao Jun Qian, Chen Fu, Bi-Cheng Wang, Yun Tian Li, Guo He Lin, Ru Bo Cao, Pin Dong Li
Publikováno v:
Oral oncology. 104
Objectives There is currently no effective salvage therapeutic modality that improves the survival outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma. However, the programmed cell death protein 1 (PD-1) and its ligand (PD-L1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2749b1ab811301dd8dd32cde6f8fad5
https://pubmed.ncbi.nlm.nih.gov/32182550
https://pubmed.ncbi.nlm.nih.gov/32182550
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 13, Pp 5969-5978 (2019)
Cancer Medicine, Vol 8, Iss 13, Pp 5969-5978 (2019)
Background Inhibitors of programmed cell death‐1 (PD‐1) and its ligand (PD‐L1) have been increasingly used in head and neck cancer therapy and reported to improve the outcomes with an acceptable safety profile. This systematic review and meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f5045dd726fe89274017c65a636f1b
https://pubmed.ncbi.nlm.nih.gov/31436392
https://pubmed.ncbi.nlm.nih.gov/31436392
Autor:
Bi-Cheng Wang, Guo-He Lin, Wang-Bing Chen, Peng-Cheng Li, Bo-Hua Kuang, Quentin Liu, Bo-Ya Xiao, Pin-Dong Li
Publikováno v:
Journal of Oncology, Vol 2021 (2021)
Background. The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d06850fe4fbd98beb5f15c5b1b5f36e
https://doi.org/10.1155/2021/3735726
https://doi.org/10.1155/2021/3735726